| Boshra George Zakhary, MD | |
|
201 S Main St Ste 1100, Danville, VA 24541-2938 | |
| (434) 792-9110 | |
| (434) 799-6074 |
| Full Name | Boshra George Zakhary |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 43 Years |
| Location | 201 S Main St Ste 1100, Danville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205872264 | NPI | - | NPPES |
| 006028039 | Medicaid | VA | |
| 065383 | Other | VA | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0101044807 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sovah Health Danville | Danville, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Danville Physician Practices Llc | 4688606304 | 61 |
News Archive
Wayne State University recently received a five-year, $1.925 million grant from the National Eye Institute of the National Institutes of Health to test the role of microRNAs (miRNAs) - a newly recognized level of gene expression regulation - in bacterial keratitis – an infection of the cornea caused by bacteria - as well as to identify new therapeutic targets and alternative treatment strategies.
For people with type 2 diabetes, the death rate from a first heart attack is two to three times the death rate of patients without the disease. Similarly, patients with diabetes and ischemic (reduced blood flow) heart disease have a much higher mortality rate than the general population.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.
› Verified 4 days ago
| Entity Name | Danville Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629022868 PECOS PAC ID: 4688606304 Enrollment ID: O20051007000454 |
News Archive
Wayne State University recently received a five-year, $1.925 million grant from the National Eye Institute of the National Institutes of Health to test the role of microRNAs (miRNAs) - a newly recognized level of gene expression regulation - in bacterial keratitis – an infection of the cornea caused by bacteria - as well as to identify new therapeutic targets and alternative treatment strategies.
For people with type 2 diabetes, the death rate from a first heart attack is two to three times the death rate of patients without the disease. Similarly, patients with diabetes and ischemic (reduced blood flow) heart disease have a much higher mortality rate than the general population.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Boshra George Zakhary, MD 201 S Main St Ste 1100, Danville, VA 24541-2938 Ph: (434) 792-9110 | Boshra George Zakhary, MD 201 S Main St Ste 1100, Danville, VA 24541-2938 Ph: (434) 792-9110 |
News Archive
Wayne State University recently received a five-year, $1.925 million grant from the National Eye Institute of the National Institutes of Health to test the role of microRNAs (miRNAs) - a newly recognized level of gene expression regulation - in bacterial keratitis – an infection of the cornea caused by bacteria - as well as to identify new therapeutic targets and alternative treatment strategies.
For people with type 2 diabetes, the death rate from a first heart attack is two to three times the death rate of patients without the disease. Similarly, patients with diabetes and ischemic (reduced blood flow) heart disease have a much higher mortality rate than the general population.
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo and other immunotherapy treatments add another critical new treatment option to fight lung cancer by harnessing the power of a patient's own immune system to fight cancerous cells.
UT Southwestern Simmons Cancer Center researchers have discovered a two-drug combo that halts the growth of cancer cells that carry HER2 mutations.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, a debilitating and almost uniformly fatal disease in which patients experience progressive difficulty breathing due to fibrosis (scarring) of the lung.
› Verified 4 days ago
Dr. Buddy Buford Stokes Ii, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1955 Memorial Dr, Danville, VA 24541 Phone: 434-799-2055 Fax: 434-799-2044 | |
Dr. Daniel Demetrios Collector, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 109 Bridge St Ste 201, Danville, VA 24541 Phone: 434-799-4488 Fax: 434-773-6977 | |
Dr. Timothy Wayne Brotherton, M,D, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 125 Executive Dr, Ste J, Danville, VA 24541 Phone: 434-793-0044 Fax: 434-792-8864 | |
Syed Aftab Ahmed, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 125 Executive Dr, Suite K, Danville, VA 24541 Phone: 434-792-7471 Fax: 434-792-1087 | |
Dr. Stecker Tam Pierson, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 125 Executive Dr Ste H, Danville, VA 24541 Phone: 434-791-1345 Fax: 434-773-6811 | |
Subash Ala, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 142 S Main St, Danville, VA 24541 Phone: 434-799-2225 | |
Sheranda C Gunn-nolan, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 142 S Main St, Danville, VA 24541 Phone: 434-799-3859 Fax: 434-773-6803 |